PMVP — PMV Pharmaceuticals Share Price
Last trade - 00:00- $75.55m
- -$107.29m
- 40
- 50
- 57
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.38 | ||
| Price to Tang. Book | 0.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.72% | ||
| Return on Equity | -23.63% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.
Directors
- Richard Heyman NEC (63)
- David Mack PRE (59)
- Winston Kung CFO (40)
- Leila Alland OTH (58)
- Deepika Jalota OTH (44)
- Kirsten Flowers DRC (46)
- Charles Baum IND (63)
- Arnold Levine IND (81)
- Thilo Schroeder IND (39)
- Laurie Stelzer IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- March 19th, 2013
- Public Since
- September 25th, 2020
- No. of Shareholders
- 7
- No. of Employees
- 63
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 51,747,130
- Address
- 400 Alexander Park Drive, Suite 301, PRINCETON, 08540
- Web
- https://www.pmvpharma.com/
- Phone
- +1 6096426670
- Auditors
- Ernst & Young LLP
Latest News for PMVP
Upcoming Events for PMVP
Q4 2024 PMV Pharmaceuticals Inc Earnings Release
Q1 2025 PMV Pharmaceuticals Inc Earnings Release
PMV Pharmaceuticals Inc Annual Shareholders Meeting
Similar to PMVP
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 21:40 UTC, shares in PMV Pharmaceuticals are trading at $1.46. This share price information is delayed by 15 minutes.
Shares in PMV Pharmaceuticals last closed at $1.46 and the price had moved by -38.27% over the past 365 days. In terms of relative price strength the PMV Pharmaceuticals share price has underperformed the S&P500 Index by -49.32% over the past year.
The overall consensus recommendation for PMV Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePMV Pharmaceuticals does not currently pay a dividend.
PMV Pharmaceuticals does not currently pay a dividend.
PMV Pharmaceuticals does not currently pay a dividend.
To buy shares in PMV Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.46, shares in PMV Pharmaceuticals had a market capitalisation of $75.55m.
Here are the trading details for PMV Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PMVP
Based on an overall assessment of its quality, value and momentum PMV Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in PMV Pharmaceuticals is $8.00. That is 447.95% above the last closing price of $1.46.
Analysts covering PMV Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.08 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PMV Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -10.7%.
As of the last closing price of $1.46, shares in PMV Pharmaceuticals were trading -10.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The PMV Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
PMV Pharmaceuticals' management team is headed by:
- Richard Heyman - NEC
- David Mack - PRE
- Winston Kung - CFO
- Leila Alland - OTH
- Deepika Jalota - OTH
- Kirsten Flowers - DRC
- Charles Baum - IND
- Arnold Levine - IND
- Thilo Schroeder - IND
- Laurie Stelzer - IND